Risk factors, therapy and survival outcomes of small cell and large cell neuroendocrine carcinoma of urinary bladder

Vijaya R Bhatt, Fausto R. Loberiza, Pavankumar Tandra, Jairam Krishnamurthy, Rajesh Shrestha, Jue Wang

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

The risk factors, the optimal therapy and prognostic factors contributing to poor outcomes of neuroendocrine urinary bladder carcinoma are not fully elucidated because of its rarity. We reviewed the medical records of neuroendocrine bladder carcinoma patients treated at the University of Nebraska Medical Center between 1996 and 2011. Eighteen patients, 55% female with a median age of 77 years, had stage IV disease at diagnosis in 50% of cases. There was a high prevalence of smoking (78%), medical co-morbidities (94%), prior cancer history (22%) and family history of cancer (61%). Treatment modalities included surgery (72%), platinum-based chemotherapy (50%) and/or radiation (22%). Median overall survival was 18.5 months (95% confidence interval, 7-36 months). Patients with Stage II and III cancer who underwent radical surgery with or without neoadjuvant chemotherapy had a median survival of 37 months. In addition to smoking, for the first time, our study indicates that the personal or family history of cancer may increase risk to neuroendocrine bladder cancer. Advanced age and stage at diagnosis, and the presence of multiple co-morbidities contribute to poor overall survival. Patients with early-stage disease are likely to benefit from a combination of radical surgery and platinum-based neoadjuvant chemotherapy.

Original languageEnglish (US)
Pages (from-to)10-14
Number of pages5
JournalRare Tumors
Volume6
Issue number1
DOIs
StatePublished - Jan 23 2014

Fingerprint

Neuroendocrine Carcinoma
Large Cell Carcinoma
Urinary Bladder
Survival
Platinum
Drug Therapy
Neoplasms
Smoking
Morbidity
Therapeutics
Urinary Bladder Neoplasms
Medical Records
Confidence Intervals
Radiation
Carcinoma

Keywords

  • Chemotherapy
  • Family history
  • Large cell neuroendocrine carcinoma of urinary bladder
  • Radical surgery
  • Small cell urinary bladder carcinoma
  • Smoking

ASJC Scopus subject areas

  • Histology
  • Oncology

Cite this

Risk factors, therapy and survival outcomes of small cell and large cell neuroendocrine carcinoma of urinary bladder. / Bhatt, Vijaya R; Loberiza, Fausto R.; Tandra, Pavankumar; Krishnamurthy, Jairam; Shrestha, Rajesh; Wang, Jue.

In: Rare Tumors, Vol. 6, No. 1, 23.01.2014, p. 10-14.

Research output: Contribution to journalReview article

Bhatt, Vijaya R ; Loberiza, Fausto R. ; Tandra, Pavankumar ; Krishnamurthy, Jairam ; Shrestha, Rajesh ; Wang, Jue. / Risk factors, therapy and survival outcomes of small cell and large cell neuroendocrine carcinoma of urinary bladder. In: Rare Tumors. 2014 ; Vol. 6, No. 1. pp. 10-14.
@article{9c34e83e43024ff086731d301aab4eb4,
title = "Risk factors, therapy and survival outcomes of small cell and large cell neuroendocrine carcinoma of urinary bladder",
abstract = "The risk factors, the optimal therapy and prognostic factors contributing to poor outcomes of neuroendocrine urinary bladder carcinoma are not fully elucidated because of its rarity. We reviewed the medical records of neuroendocrine bladder carcinoma patients treated at the University of Nebraska Medical Center between 1996 and 2011. Eighteen patients, 55{\%} female with a median age of 77 years, had stage IV disease at diagnosis in 50{\%} of cases. There was a high prevalence of smoking (78{\%}), medical co-morbidities (94{\%}), prior cancer history (22{\%}) and family history of cancer (61{\%}). Treatment modalities included surgery (72{\%}), platinum-based chemotherapy (50{\%}) and/or radiation (22{\%}). Median overall survival was 18.5 months (95{\%} confidence interval, 7-36 months). Patients with Stage II and III cancer who underwent radical surgery with or without neoadjuvant chemotherapy had a median survival of 37 months. In addition to smoking, for the first time, our study indicates that the personal or family history of cancer may increase risk to neuroendocrine bladder cancer. Advanced age and stage at diagnosis, and the presence of multiple co-morbidities contribute to poor overall survival. Patients with early-stage disease are likely to benefit from a combination of radical surgery and platinum-based neoadjuvant chemotherapy.",
keywords = "Chemotherapy, Family history, Large cell neuroendocrine carcinoma of urinary bladder, Radical surgery, Small cell urinary bladder carcinoma, Smoking",
author = "Bhatt, {Vijaya R} and Loberiza, {Fausto R.} and Pavankumar Tandra and Jairam Krishnamurthy and Rajesh Shrestha and Jue Wang",
year = "2014",
month = "1",
day = "23",
doi = "10.4081/rt.2014.5043",
language = "English (US)",
volume = "6",
pages = "10--14",
journal = "Rare Tumors",
issn = "2036-3605",
publisher = "PagePress",
number = "1",

}

TY - JOUR

T1 - Risk factors, therapy and survival outcomes of small cell and large cell neuroendocrine carcinoma of urinary bladder

AU - Bhatt, Vijaya R

AU - Loberiza, Fausto R.

AU - Tandra, Pavankumar

AU - Krishnamurthy, Jairam

AU - Shrestha, Rajesh

AU - Wang, Jue

PY - 2014/1/23

Y1 - 2014/1/23

N2 - The risk factors, the optimal therapy and prognostic factors contributing to poor outcomes of neuroendocrine urinary bladder carcinoma are not fully elucidated because of its rarity. We reviewed the medical records of neuroendocrine bladder carcinoma patients treated at the University of Nebraska Medical Center between 1996 and 2011. Eighteen patients, 55% female with a median age of 77 years, had stage IV disease at diagnosis in 50% of cases. There was a high prevalence of smoking (78%), medical co-morbidities (94%), prior cancer history (22%) and family history of cancer (61%). Treatment modalities included surgery (72%), platinum-based chemotherapy (50%) and/or radiation (22%). Median overall survival was 18.5 months (95% confidence interval, 7-36 months). Patients with Stage II and III cancer who underwent radical surgery with or without neoadjuvant chemotherapy had a median survival of 37 months. In addition to smoking, for the first time, our study indicates that the personal or family history of cancer may increase risk to neuroendocrine bladder cancer. Advanced age and stage at diagnosis, and the presence of multiple co-morbidities contribute to poor overall survival. Patients with early-stage disease are likely to benefit from a combination of radical surgery and platinum-based neoadjuvant chemotherapy.

AB - The risk factors, the optimal therapy and prognostic factors contributing to poor outcomes of neuroendocrine urinary bladder carcinoma are not fully elucidated because of its rarity. We reviewed the medical records of neuroendocrine bladder carcinoma patients treated at the University of Nebraska Medical Center between 1996 and 2011. Eighteen patients, 55% female with a median age of 77 years, had stage IV disease at diagnosis in 50% of cases. There was a high prevalence of smoking (78%), medical co-morbidities (94%), prior cancer history (22%) and family history of cancer (61%). Treatment modalities included surgery (72%), platinum-based chemotherapy (50%) and/or radiation (22%). Median overall survival was 18.5 months (95% confidence interval, 7-36 months). Patients with Stage II and III cancer who underwent radical surgery with or without neoadjuvant chemotherapy had a median survival of 37 months. In addition to smoking, for the first time, our study indicates that the personal or family history of cancer may increase risk to neuroendocrine bladder cancer. Advanced age and stage at diagnosis, and the presence of multiple co-morbidities contribute to poor overall survival. Patients with early-stage disease are likely to benefit from a combination of radical surgery and platinum-based neoadjuvant chemotherapy.

KW - Chemotherapy

KW - Family history

KW - Large cell neuroendocrine carcinoma of urinary bladder

KW - Radical surgery

KW - Small cell urinary bladder carcinoma

KW - Smoking

UR - http://www.scopus.com/inward/record.url?scp=84892958013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892958013&partnerID=8YFLogxK

U2 - 10.4081/rt.2014.5043

DO - 10.4081/rt.2014.5043

M3 - Review article

C2 - 24711904

AN - SCOPUS:84892958013

VL - 6

SP - 10

EP - 14

JO - Rare Tumors

JF - Rare Tumors

SN - 2036-3605

IS - 1

ER -